U.S. Physical Therapy Stock Price Target and Analyst Ratings (NYSE:USPH)

Analyst Price Target for USPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$90.00

▼ -20.74% Downside Potential

This price target is based on 3 analysts offering 12 month price targets for U.S. Physical Therapy in the last 3 months. The average price target is $90.00, with a high forecast of $100.00 and a low forecast of $80.00. The average price target represents a -20.74% upside from the last price of $113.55.

Hold

The current consensus among 3 investment analysts is to hold stock in U.S. Physical Therapy. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/10/2019

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/9/2019

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/8/2020

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/6/2020

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/4/2020

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/3/2020

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/1/2021

0 strong buy ratings
0 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/3/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/26/2021	Barrington Research	Downgrade	Outperform ➝ Market Perform		Low	i Rating by M. Petusky at Barrington Research
8/7/2020	Barrington Research	Boost Price Target	Outperform	$95.00 ➝ $100.00	Low	i
6/8/2020	Barrington Research	Boost Price Target	Outperform	$84.00 ➝ $95.00	Low	i
4/30/2020	Sidoti	Downgrade	Buy ➝ Neutral		High	i Rating by Mitra Ramgopal at Sidoti
3/27/2020	Sidoti	Lower Price Target	Buy	$128.00 ➝ $80.00	Medium	i Rating by Mitra Ramgopal at Sidoti
3/17/2020	William Blair	Downgrade	Outperform ➝ Hold		High	i Rating by Matt Larew at William Blair
3/11/2020	Sidoti	Upgrade	Neutral ➝ Buy	$128.00	Medium	i
2/28/2020	Barrington Research	Lower Price Target	Outperform	$130.00 ➝ $120.00	High	i Rating by M. Petusky at Barrington Research
1/31/2020	William Blair	Reiterated Rating	Buy		Medium	i Rating by Matt Larew at William Blair
11/8/2019	Barrington Research	Upgrade	Market Perform ➝ Outperform	$130.00	High	i Rating by M. Petusky at Barrington Research
5/3/2019	Barrington Research	Reiterated Rating	Hold		Low	i
3/7/2019	William Blair	Initiated Coverage	Outperform ➝ Outperform	$106.61	Medium	i Rating by M. Larew at William Blair
11/2/2018	Cantor Fitzgerald	Boost Price Target	Neutral ➝ Neutral	$103.00 ➝ $107.00	Low	i Rating by J. France at Cantor Fitzgerald
8/3/2018	Jefferies Financial Group	Reiterated Rating	Hold	$105.00	Low	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/3/2018	Barrington Research	Reiterated Rating	Hold		Medium	i
5/4/2018	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low	i Rating by J. France at Cantor Fitzgerald
5/3/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Buy	$90.00	Low	i
4/25/2018	Sidoti	Downgrade	Buy ➝ Neutral		High	i
3/9/2018	Cantor Fitzgerald	Boost Price Target	Overweight	$90.00	Low	i
3/9/2018	Barrington Research	Reiterated Rating	Hold		High	i Rating by M. Petusky at Barrington Research
2/23/2018	Jefferies Financial Group	Set Price Target	Hold	$76.00	Low	i
1/9/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$80.00	Low	i Rating by J. France at Cantor Fitzgerald
11/3/2017	Barrington Research	Downgrade	Outperform ➝ Market Perform		N/A	i Rating by M. Petusky at Barrington Research
11/2/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$74.00	N/A	i Rating by J. France at Cantor Fitzgerald
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$72.00	Low	i Rating by J. France at Cantor Fitzgerald
9/8/2017	Sidoti	Upgrade	Neutral ➝ Buy	$62.00 ➝ $74.00	Low	i
8/4/2017	Jefferies Financial Group	Set Price Target	Hold	$65.00	Low	i
7/24/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$72.00	High	i Rating by J. France at Cantor Fitzgerald
7/3/2017	Barrington Research	Upgrade	Market Perform ➝ Outperform	$68.00	High	i Rating by M. Petusky at Barrington Research
6/30/2017	Jefferies Financial Group	Reiterated Rating	Hold	$63.00	Low	i
3/18/2017	Jefferies Financial Group	Set Price Target	Hold	$63.00	Low	i
3/17/2017	Barrington Research	Downgrade	Outperform ➝ Market Perform		High	i Rating by M. Petusky at Barrington Research
12/5/2016	Jefferies Financial Group	Reiterated Rating	Hold	$60.00 ➝ $63.00	N/A	i
11/7/2016	JMP Securities	Reiterated Rating	Hold		N/A	i
11/7/2016	Jefferies Financial Group	Lower Price Target	Hold	$60.00	N/A	i
11/4/2016	Barrington Research	Upgrade	Market Perform ➝ Outperform	$61.00	N/A	i Rating by M. Petusky at Barrington Research
8/5/2016	Jefferies Financial Group	Set Price Target	Hold	$53.00 ➝ $65.00	N/A	i
8/5/2016	Barrington Research	Downgrade	Outperform ➝ Market Perform		N/A	i Rating by M. Petusky at Barrington Research
5/6/2016	Barrington Research	Upgrade	Market Perform ➝ Outperform	$58.00	N/A	i Rating by M. Petusky at Barrington Research

(Data available from 3/3/2016 forward)

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of October 9, 2020, it operated 549 outpatient physical therapy clinics in 39 states; and managed 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The company was founded in 1990 and is based in Houston, Texas.

Today's Range

Now: $113.55

$113.21

$116.70

50 Day Range

MA: $130.63

$116.31

$141.60

52 Week Range

Now: $113.55

$45.13

$143.67

Volume

85,394 shs

Average Volume

71,831 shs

Market Capitalization

$1.46 billion

P/E Ratio

48.32

Dividend Yield

0.28%

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of U.S. Physical Therapy?

The following Wall Street research analysts have issued research reports on U.S. Physical Therapy in the last twelve months: Barrington Research, Sidoti, William Blair, and Zacks Investment Research.
View the latest analyst ratings for USPH.

What is the current price target for U.S. Physical Therapy?

2 Wall Street analysts have set twelve-month price targets for U.S. Physical Therapy in the last year. Their average twelve-month price target is $90.00, suggesting a possible downside of 20.7%. Barrington Research has the highest price target set, predicting USPH will reach $100.00 in the next twelve months. Sidoti has the lowest price target set, forecasting a price of $80.00 for U.S. Physical Therapy in the next year.
View the latest price targets for USPH.

What is the current consensus analyst rating for U.S. Physical Therapy?

U.S. Physical Therapy currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in USPH, but not buy more shares or sell existing shares.
View the latest ratings for USPH.

What other companies compete with U.S. Physical Therapy?

Other companies that are similar to U.S. Physical Therapy include HCA Healthcare, Alcon, Universal Health Services, Tenet Healthcare, Acadia Healthcare, Select Medical, The Ensign Group, Community Health Systems, Brookdale Senior Living, National HealthCare, Five Star Senior Living, Capital Senior Living and Encompass Health.

How do I contact U.S. Physical Therapy's investor relations team?

U.S. Physical Therapy's physical mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company's listed phone number is 713-297-7000 and its investor relations email address is [email protected] The official website for U.S. Physical Therapy is www.usph.com.

NYSE:USPH - U.S. Physical Therapy Stock Price Target and Predictions

Analyst Price Target for USPH

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of U.S. Physical Therapy?

What is the current price target for U.S. Physical Therapy?

What is the current consensus analyst rating for U.S. Physical Therapy?

What other companies compete with U.S. Physical Therapy?

How do I contact U.S. Physical Therapy's investor relations team?